
|Videos|December 14, 2022
Appropriate Patient Selection for Patients with HER2+ Metastatic Colorectal Cancer for Anti-HER2 Therapies
Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
2
The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?
3
Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma
4
What Does an End-of-Life Doula Do for Patients With Cancer?
5





























































